Studies reveal immune response features and better model for glioblastoma therapy
Two UCLA-led studies examined why immunotherapy often fails in glioblastoma and what an effective immune response looks like in patients who survive long-term after checkpoint inhibitor treatment. One study identified immune features linked to extended survival, while the other created a preclinical model that more closely mimics human glioblastoma. The researchers say these tools could improve development and testing of next-generation treatments.
The UCLA-led work centers on glioblastoma, an aggressive brain cancer that often returns after surgery, radiation, and chemotherapy and has responded poorly to immunotherapy. In a phase 2 trial, 63 patients with recurrent tumors received nivolumab plus ipilimumab, nivolumab alone, or placebo before surgery. The combination group survived a median of about 13.5 months versus roughly nine months for nivolumab alone; five combination recipients became long-term survivors, while none did on nivolumab alone.
Tumor tissue showed greater T-cell infiltration and higher interferon-related gene activity after combination treatment. T-cell density independently predicted longer survival. A second study introduced a preclinical model intended to mirror human glioblastoma more closely, giving researchers a stricter platform for testing future therapies.
If validated, these findings could inform future trial design and help identify patients most likely to benefit from checkpoint inhibition. People with recurrent glioblastoma and their families may gain from clearer prognostic signals and better preclinical testing, though benefits would likely take years to reach care. Researchers and drug developers might use the model to prioritize combinations, potentially reducing late-stage failures. Any societal impact would depend on replication, access, and whether new treatments improve survival without worsening quality of life.